India hopes to gain strategically with the signing of a new order by the US President on medical products.

New executive order signed by US President Donald Trump ensuring that US government agencies purchase all the essential medicines it needs from American sources is going to benefit India.

Quoting government sources, WION said, “Objectives of these measures are targetted mainly at China.” The US President’s order on essential drugs “may benefit India strategically."

In his address to workers at Ohio, US President Trump stressed on domestic production of “essential equipment, supplies and pharmaceuticals” so that the US doesn't need to rely on other nations for them.

China is the world's largest source of Active Pharmaceutical Ingredients (APIs) with India also importing vast quantities from the country.

Quoting sources the report says development of API and critical medicine manufacturing in the US could be a positive development for India in terms of national security considerations and could provide non-China sources.

India, which had sent hydroxychloroquine (HCQ) to the US amidst the coronavirus pandemic, shares a substantial relationship with America when it comes to the pharma sector. Indian pharmaceutical companies like Cipla, Sun Pharma, Dr Reddy’s and others are present in the US market.

Read the full article in WION: